检索结果-南通市图书馆

Effects of Serum from a Fibrodysplasia Ossificans Progressiva Patient on Osteoblastic Cells

Open Journal of Endocrine and Metabolic Diseases 2012年第1期2卷 1-6页

作者： Itoko Hisa Akira Kawara Takenobu Katagiri Toshitsugu Sugimoto Hiroshi Kaji Division of Diabetes and Endocrinology Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan Division of Pathophysiology Research Center for Genomic Medicine Saitama Medical University Japan Internal Medicine 1 Shimane University Faculty of Medicine Izumo Japan Kawara Clinic Kobe Japan

Introduction: Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder of skeletal malformations and progressive extraskeletal ossification. Patients and Methods: In the present study, we present a case of FOP with marked progressive ossification of extraskeletal tissues. We investigated whether soluble factors in serum would affect the osteoblast phenotype by examining the effects of serum from this patient and control subjects on mouse osteoblastic MC3T3-E1 cells. Results: The clinical findings of this patient were compatible with FOP, and direct sequence analysis of genomic DNA demonstrated the presence of a heterozygous 617G> A (R206H) mutation of activin type 1 receptor (ACVR1). Serum from the FOP patient enhanced the level of alkaline phosphatase (ALP) in Western blotting, compared with serum from the control, in MC3T3-E1 cells. Moreover, serum from the FOP patient enhanced the levels of ALP, osteocalcin and bone morphogenetic protein-2 mRNA in these cells. Conclusion: We presented a case of FOP with progressive ossification in extra-skeletal tissues with ACVR1 mutation. The present data suggest that the serum from this patient includes some soluble factors, which might enhance the osteoblast differentiation and BMP-2 expression in mouse osteoblastic cells.

关键词： Fibrodysplasia Ossificans Progressiva Osteoblast Bone Morphogenetic Protein

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Randomized study of lafutidine vs lansoprazole in patients with mild gastroesophageal reflux disease

引用

World Journal of Gastroenterology 2016年第23期22卷 5430-5435页

作者： Ryuta Takenaka Hiroyuki Okada Seiji Kawano Yoshinori Komazawa Fumiya Yoshinaga Shinji Nagata Masafumi Inoue Hirohisa Komatsu Seiji Onogawa Yoshinori Kushiyama Shinichi Mukai Hiroko Todo Hideharu Okanobu Noriaki Manabe Shinji Tanaka Ken Haruma Yoshikazu Kinoshita Department of Gastroenterology Tsuyama Chuo Hospital Tsuyama 708-0841 Japan Department of Gastroenterology and Hepatology Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences Okayama 708-0841 Japan Division of Internal Medicine Izumo City General Medical Center Izumo 691-0003 Japan Department of Gastroenterology Mihara Red Cross Hospital Mihara 723-0011 Japan Department of Endoscopy Hiroshima City Asa Citizens Hospital Hiroshima 731-0293 Japan Department of Gastroenterology Okayama Red Cross Hospital Okayama 700-0941 Japan Department of Gastroenterology Hiroshima General Hospital Hiroshima 734-8551 Japan Department of Gastroenterology Onomichi General Hospital Onomichi 722-8508 Japan Department of Gastroenterology Matsue Red Cross Hospital Matsue 690-8506 Japan Department of Gastroenterology Miyoshi Central Hospital Miyoshi 728-0023 Japan Department of Gastroenterology Hiroshima-Nishi Medical Center Hiroshima 739-0651 Japan Department of Gastroenterology Chugoku Rosai Hospital Kure 737-0134 Japan Department of Gastroenterology Kawasaki Medical School Hospital Kurashiki 701-0192 Japan Department of Endoscopy Hiroshima University Hospital Hiroshima 734-8551 Japan Department of General Internal Medicine 2 Kawasaki Hospital Kawasaki Medical School Okayama 708-0841 Japan Department of Gastroenterology and Hepatology Shimane University Hospital Izumo 693-0021 Japan

AIM: To compare the clinical efficacy of the secondgeneration H2 RA lafutidine with that of lansoprazole in Japanese patients with mild gastroesophageal reflux disease(GERD). METHODS: Patients with symptoms of GERD and a diagnosis of grade A reflux esophagitis(according to the Los Angeles classification) were randomized to receive lafutidine(10 mg, twice daily) or lansoprazole(30 mg, once daily) for an initial 8 wk, followed by maintenance treatment comprising half-doses of the assigned drug for 24 wk. The primary endpoint was the frequency and severity of heartburn during initial and maintenance treatment. The secondary endpoints were the sum score of questions 2 and 3 in the Gastrointestinal Symptom Rating Scale(GSRS), and the satisfaction ***: Between April 2012 and March 2013, a total of 53 patients were enrolled, of whom 24 and 29 received lafutidine and lansoprazole, respectively. After 8 wk, the frequency and severity of heartburn was significantly reduced in both groups. However, lafutidine was significantly inferior to lansoprazole with regard to the severity of heartburn during initial and maintenance treatment(P = 0.016). The sum score of questions 2 and 3 in the GSRS, and satisfaction scores were also significantly worse in the lafutidine group than the lansoprazole group(P = 0.0068 and P = 0.0048, respectively).CONCLUSION: The clinical efficacy of lafutidine was inferior to that of lansoprazole, even in Japanese patients with mild GERD.

关键词： Gastroesophageal reflux disease Proton pump inhibitors Histamine receptor-2 antagonists Los Angeles classification

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：